Pro Medicus Pulls Back from A$200 Resistance Despite Fresh US$25 Million Contract Win

Pro Medicus shares (ASX: PME) fell back 7% on Friday, despite announcing another major US healthcare contract, as technical resistance and profit-taking overwhelmed positive fundamental news in a week that still delivered solid gains for the fourth week running.

The Pro Medicus share price heads into today’s session at A$191.60, pulling back from the psychologically important A$200 level ahead of the weekend, after testing a breakout earlier in the week.

Despite the pullback into the weekend, PME still finished the week 7.12% higher and trading more than 75% up from its 52-week low of A$107.75. The Friday sell-off appeared driven by technical factors and a sector wide pause rather than fundamental concerns, with healthcare names coming under pressure after a strong rally.

Contract Momentum Building

The new week begins with markets digesting a seven-year, A$25 million contract with Valley Health, a United States-based healthcare provider. The agreement covers Pro Medicus’s full suite of cloud-based medical imaging solutions, including the Visage 7 Viewer, Workflow, Open Archive, and Cardiology Imaging modules.

The contract will be delivered using Pro Medicus’s cloud-based, transaction-based pricing model, which allows revenue to scale with imaging volumes over time. Valley Health will migrate its legacy Picture Archiving and Communication System archive to the Visage 7 Open Archive platform, with implementation targeted for the first quarter of calendar year 2027.

While the A$25 million contract value is modest compared to some of Pro Medicus’s recent mega-deals, it reinforces the company’s growing penetration across both academic medical centres and community health systems in North America. The agreement marks another validation of the firm’s CloudPACS strategy and its positioning as a full-stack enterprise imaging provider capable of displacing legacy on-premise systems.

Record FY26 Supports PME Rally

The Valley Health contract adds to what has been a transformational fiscal year for Pro Medicus. On Tuesday (18th), the company reported FY26 results that exceeded market expectations across virtually every metric, with net profit after tax surging approximately 130% to around A$265 million when including one-off items, and underlying NPAT climbing roughly 24% to approximately A$145 million.

Revenue for the year rose about 23% to A$262 million, driven primarily by strong growth in transaction-based cloud contracts as implementations from prior-year signings began contributing to the top line. Underlying EBIT expanded at a similar 24% pace, demonstrating the operating leverage inherent in Pro Medicus’s software-as-a-service business model as scale builds.

The FY26 contract book was equally impressive. Pro Medicus signed ten new contracts with a combined minimum value of approximately A$407 million, while renewals brought total new and renewal contract value to around A$548 million for the year. Significantly, the company renewed all six contracts that came up for tender during the period, upgrading them to new five-year terms and demonstrating the stickiness of its platform once deployed.

Headline wins during FY26 included a ten-year, A$170 million full-stack contract with UC Health Colorado, one of the largest deals in company history, and a seven-year, A$90 million agreement with Beth Israel Lahey Health covering full enterprise imaging on a cloud basis. Other material contracts included University of Maryland (five years, A$23 million), TidalHealth (seven years, A$16 million), and most recently St. Luke’s (seven years, A$23 million, announced 12 August).

Major renewals during the year featured Northwestern Medicine (five years, A$37 million), MedStar Health (five years, approximately A$31 million), and Allegheny Health Network (five years, A$28 million), all on expanded terms relative to their original agreements.

Pro Medicus also increased its total FY26 dividend to approximately 69 cents per share, up around 25% year-on-year, while maintaining a debt-free balance sheet with growing cash and financial asset balances. The company has continued to allocate capital through on-market share buybacks and strategic minority investments in complementary imaging technology firms including 4D Medical and EchoIQ.

What Lay Ahead?

Pro Medicus shares have previously been caught in rotations away from expensive healthcare IT and software names when rate expectations shift or when investors question the earnings visibility of high-multiple growth stories. That pattern appears relevant, with periodic bouts of selling when volatility rises or when the macro backdrop prompts a preference for cheaper, more defensive exposures.

The average price target on the stock at A$213.32 implies more than 10% upside from here, with the current technical setup also bullish. The stock price remains above both the 50 day and 200 day SMA, although the volatility has expanded sharply, up around 31% from the prior reading. This suggests range expansion and the kind of big price swings that tend to accompany both momentum rallies and the corrections that follow.

With a contracted revenue base now in the hundreds of millions and a market capitalisation of A$20 billion at current prices, Pro Medicus will need to continue signing deals on a regular basis to sustain its growth trajectory. The bar for positive surprises has risen meaningfully, and markets are likely to react more sensitively to any perceived gap in deal flow or softness in guidance.

From a macro perspective, Pro Medicus operates with some insulation from economic cycles due to the non-discretionary nature of medical imaging, but it is not immune to broader healthcare sector trends. Four positive weeks for the stock will have bulls feeling optimistic about what lay ahead, but with the stock already up 77% in just under 6 months, there is now plenty more priced in.